Scribe Therapeutics priced an upsized initial public offering of 8.58 million shares at $15, raising $128.7 million gross before expenses and the underwriters’ option. Trading is expected to begin July 24 under SCTX, with…
Sanofi discontinued development of amlitelimab in moderate-to-severe atopic dermatitis and will not seek global approval after concluding that the totality of efficacy and safety did not support further development. The decision is strategically important…
The FDA approved subcutaneous Sarclisa (isatuximab-irfc) Escena across all existing Sarclisa IV indications in multiple myeloma. It is the first anticancer treatment administered via an on-body injector, and the first myeloma therapy available by…
